Takeda Pharmaceutical (NYSE:TAK) Raised to Strong-Buy at Zacks Research

Takeda Pharmaceutical (NYSE:TAK) was upgraded by stock analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a note issued to investors on Wednesday, Zacks reports.

A number of other brokerages also recently issued reports on TAK. Weiss Ratings downgraded Takeda Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Thursday, July 30th. Wall Street Zen raised shares of Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Saturday, July 18th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy”.

Takeda Pharmaceutical Price Performance

Shares of TAK opened at $18.71 on Wednesday. The firm has a fifty day simple moving average of $17.26 and a two-hundred day simple moving average of $17.20. Takeda Pharmaceutical has a 1-year low of $12.99 and a 1-year high of $18.90. The company has a current ratio of 1.14, a quick ratio of 0.62 and a debt-to-equity ratio of 0.58. The firm has a market cap of $59.95 billion, a PE ratio of 55.03 and a beta of -0.07.

Takeda Pharmaceutical (NYSE:TAK) last released its earnings results on Thursday, July 30th. The company reported $0.95 earnings per share for the quarter, beating the consensus estimate of $0.41 by $0.54. Takeda Pharmaceutical had a return on equity of 10.95% and a net margin of 3.80%.The company had revenue of $7.50 billion for the quarter, compared to the consensus estimate of $7.13 billion. Takeda Pharmaceutical has set its FY 2026 guidance at 3.009-3.009 EPS. On average, equities analysts anticipate that Takeda Pharmaceutical will post 1.54 EPS for the current year.

Insider Transactions at Takeda Pharmaceutical

In related news, insider Giles Platford sold 31,083 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $17.10, for a total value of $531,519.30. Following the transaction, the insider directly owned 315,838 shares in the company, valued at approximately $5,400,829.80. This represents a 8.96% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Deidre Greenway sold 12,980 shares of the stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $18.11, for a total transaction of $235,067.80. Following the transaction, the insider directly owned 40,049 shares of the company’s stock, valued at approximately $725,287.39. This trade represents a 24.48% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 592,922 shares of company stock valued at $10,340,896. Insiders own 0.04% of the company’s stock.

Institutional Trading of Takeda Pharmaceutical

Hedge funds have recently modified their holdings of the stock. Arrowstreet Capital Limited Partnership lifted its stake in Takeda Pharmaceutical by 100.9% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 5,682,847 shares of the company’s stock worth $88,596,000 after acquiring an additional 2,854,069 shares during the last quarter. UBS Group AG grew its stake in shares of Takeda Pharmaceutical by 46.4% in the 3rd quarter. UBS Group AG now owns 5,893,969 shares of the company’s stock valued at $86,288,000 after purchasing an additional 1,869,323 shares during the last quarter. Qube Research & Technologies Ltd raised its holdings in Takeda Pharmaceutical by 407.9% during the third quarter. Qube Research & Technologies Ltd now owns 1,775,845 shares of the company’s stock worth $25,998,000 after purchasing an additional 1,426,184 shares in the last quarter. Van ECK Associates Corp lifted its stake in shares of Takeda Pharmaceutical by 98.4% in the fourth quarter. Van ECK Associates Corp now owns 2,305,397 shares of the company’s stock valued at $35,941,000 after purchasing an additional 1,143,117 shares during the period. Finally, Voloridge Investment Management LLC boosted its position in shares of Takeda Pharmaceutical by 1,070.7% in the 4th quarter. Voloridge Investment Management LLC now owns 962,502 shares of the company’s stock worth $15,005,000 after buying an additional 880,289 shares in the last quarter. 9.17% of the stock is currently owned by institutional investors and hedge funds.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.